FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308395731> ?p ?o ?g. }

• W4308395731 abstract "<h3>Background</h3> NOUS-PEV is a vector based personalized cancer vaccine, expressing about 60 patient specific neoantigens identified by next generation sequencing (NGS). Vaccination consists of Great Ape Adenoviral (GAd) prime followed by Modified Vaccinia Ankara (MVA) boosts. The study is a dose-confirmation and cohort expansion, phase 1b, first in human (FIH) trial (NCT04990479) evaluating safety, tolerability, immunogenicity and preliminary anti-tumour activity of NOUS-PEV in combination with the PD-1 blocking antibody pembrolizumab. <h3>Methods</h3> The study is enrolling treatment-naïve subjects with unresectable stage III/IV cutaneous melanoma and/or PD ligand 1 (PD-L1) ≥ 50% stage IV non-small cell lung cancer. Following pembrolizumab induction treatment (3 cycles), the vaccines are administered intramuscularly: the GAd priming dose concomitantly with pembrolizumab at week 10 (4th pembrolizumab infusion) followed by 3 boosts of MVA, each 3 weeks apart. Baseline and on treatment tumor biopsies are collected at screening and post 1st MVA, respectively. PBMC are collected at baseline, post pembrolizumab, and post each vaccination for evaluation of immune response. Clinical response is evaluated according to RECIST v1.1 by CT scan according to standard of care. <h3>Results</h3> All vaccines were made and administered on time to the three melanoma subjects in the dose-confirmation cohort. As of June 2022, the median follow-up is 6.9 months (range 3.0-11.5). No dose limiting toxicities (DLTs) were observed, and the treatment was safe and no NOUS-PEV related AEs >Grade 1 were observed, allowing the enrollment of subjects in the expansion cohort. In the first subject, the first CT scan before vaccination showed initial SD with dynamic of growth in target lesion size, that then reverted after NOUS-PEV administration, resulting in a confirmed PR deepening over time. The second subject had a PR already at the first CT scan, further deepened after the vaccination. The third subject had PD at the first scan before vaccination and discontinued based on the confirmatory scan. Vaccine-induced immunogenicity was demonstrated by <i>ex-vivo</i> interferon-gamma ELISpot in 2 evaluable subjects who showed clinical response, with detection of potent neoantigen specific immune response to multiple neoantigens in the peripheral blood and induction of both CD4 and CD8 T cell responses. NGS analysis of baseline and on-treatment biopsies showed an increased T cell infiltrate, with expansion and diversification of the TCR repertoire post treatment. <h3>Conclusions</h3> NOUS-PEV in combination with anti-PD1 is safe and well tolerated. Data show that vaccination elicits a robust immune response which correlates with preliminary clinical activity. <h3>Trial Registration</h3> NCT04990479 <h3>Ethics Approval</h3> The study was approved by UZ Leuven Ethics Committee (Study Reference S64578) and by Research Ethics Committee of Fundacion Jimenez Diaz, Madrid" @default.
• W4308395731 created "2022-11-11" @default.
• W4308395731 creator A5005521408 @default.
• W4308395731 creator A5006600730 @default.
• W4308395731 creator A5006663756 @default.
• W4308395731 creator A5013742096 @default.
• W4308395731 creator A5020793508 @default.
• W4308395731 creator A5021066316 @default.
• W4308395731 creator A5027457496 @default.
• W4308395731 creator A5035993804 @default.
• W4308395731 creator A5055345185 @default.
• W4308395731 creator A5058642751 @default.
• W4308395731 creator A5063622946 @default.
• W4308395731 creator A5070469478 @default.
• W4308395731 creator A5072652271 @default.
• W4308395731 creator A5073524051 @default.
• W4308395731 creator A5082056132 @default.
• W4308395731 creator A5085237357 @default.
• W4308395731 creator A5087218547 @default.
• W4308395731 creator A5087791595 @default.
• W4308395731 date "2022-11-01" @default.
• W4308395731 modified "2023-10-18" @default.
• W4308395731 title "706 NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study" @default.
• W4308395731 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0706" @default.
• W4308395731 hasPublicationYear "2022" @default.
• W4308395731 type Work @default.
• W4308395731 citedByCount "0" @default.
• W4308395731 crossrefType "proceedings-article" @default.
• W4308395731 hasAuthorship W4308395731A5005521408 @default.
• W4308395731 hasAuthorship W4308395731A5006600730 @default.
• W4308395731 hasAuthorship W4308395731A5006663756 @default.
• W4308395731 hasAuthorship W4308395731A5013742096 @default.
• W4308395731 hasAuthorship W4308395731A5020793508 @default.
• W4308395731 hasAuthorship W4308395731A5021066316 @default.
• W4308395731 hasAuthorship W4308395731A5027457496 @default.
• W4308395731 hasAuthorship W4308395731A5035993804 @default.
• W4308395731 hasAuthorship W4308395731A5055345185 @default.
• W4308395731 hasAuthorship W4308395731A5058642751 @default.
• W4308395731 hasAuthorship W4308395731A5063622946 @default.
• W4308395731 hasAuthorship W4308395731A5070469478 @default.
• W4308395731 hasAuthorship W4308395731A5072652271 @default.
• W4308395731 hasAuthorship W4308395731A5073524051 @default.
• W4308395731 hasAuthorship W4308395731A5082056132 @default.
• W4308395731 hasAuthorship W4308395731A5085237357 @default.
• W4308395731 hasAuthorship W4308395731A5087218547 @default.
• W4308395731 hasAuthorship W4308395731A5087791595 @default.
• W4308395731 hasBestOaLocation W43083957311 @default.
• W4308395731 hasConcept C121608353 @default.
• W4308395731 hasConcept C126322002 @default.
• W4308395731 hasConcept C143998085 @default.
• W4308395731 hasConcept C197934379 @default.
• W4308395731 hasConcept C203014093 @default.
• W4308395731 hasConcept C22070199 @default.
• W4308395731 hasConcept C2777701055 @default.
• W4308395731 hasConcept C2778375690 @default.
• W4308395731 hasConcept C2780057760 @default.
• W4308395731 hasConcept C2780674031 @default.
• W4308395731 hasConcept C71924100 @default.
• W4308395731 hasConceptScore W4308395731C121608353 @default.
• W4308395731 hasConceptScore W4308395731C126322002 @default.
• W4308395731 hasConceptScore W4308395731C143998085 @default.
• W4308395731 hasConceptScore W4308395731C197934379 @default.
• W4308395731 hasConceptScore W4308395731C203014093 @default.
• W4308395731 hasConceptScore W4308395731C22070199 @default.
• W4308395731 hasConceptScore W4308395731C2777701055 @default.
• W4308395731 hasConceptScore W4308395731C2778375690 @default.
• W4308395731 hasConceptScore W4308395731C2780057760 @default.
• W4308395731 hasConceptScore W4308395731C2780674031 @default.
• W4308395731 hasConceptScore W4308395731C71924100 @default.
• W4308395731 hasLocation W43083957311 @default.
• W4308395731 hasOpenAccess W4308395731 @default.
• W4308395731 hasPrimaryLocation W43083957311 @default.
• W4308395731 hasRelatedWork W2030612376 @default.
• W4308395731 hasRelatedWork W2342781363 @default.
• W4308395731 hasRelatedWork W2893846263 @default.
• W4308395731 hasRelatedWork W2969782175 @default.
• W4308395731 hasRelatedWork W2970048128 @default.
• W4308395731 hasRelatedWork W2996772275 @default.
• W4308395731 hasRelatedWork W3153432702 @default.
• W4308395731 hasRelatedWork W3161613553 @default.
• W4308395731 hasRelatedWork W3195008613 @default.
• W4308395731 hasRelatedWork W3215044659 @default.
• W4308395731 isParatext "false" @default.
• W4308395731 isRetracted "false" @default.
• W4308395731 workType "article" @default.